Repatha vs Praluent: Switching Between Evolocumab and Alirocumab

How PCSK9 Inhibitors Work

Both Repatha and Praluent block proprotein convertase subtilisin/kexin type 9, a liver enzyme that degrades LDL receptors on hepatocyte surfaces. When PCSK9 is neutralized, more LDL receptors recycle back to the cell surface and pull LDL particles out of circulation. The result is a rapid, substantial drop in LDL-C that begins within days of the first injection.

The two drugs share an identical mechanism. Both are fully human IgG monoclonal antibodies produced via recombinant DNA technology, though they bind slightly different epitopes on the PCSK9 protein [1][2]. This mechanistic overlap means clinical outcomes are remarkably similar. A 2019 meta-analysis in the Journal of the American Heart Association pooling data from 39 trials (66,478 patients total) found no statistically significant difference in LDL-C lowering or cardiovascular event reduction between evolocumab and alirocumab [3]. Neither drug affects HDL or triglycerides in a clinically meaningful way, though small increases in HDL (5-8%) have been reported in both the FOURIER and ODYSSEY programs.

The practical distinction is not pharmacologic. It is logistical.

FOURIER vs ODYSSEY OUTCOMES: The Landmark Trials

The FOURIER trial (N=27,564) randomized patients with stable atherosclerotic cardiovascular disease (ASCVD) on statin therapy to evolocumab or placebo. Over a median follow-up of 2.2 years, evolocumab reduced the primary composite endpoint (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization) by 15% (HR 0.85, 95% CI 0.79-0.92, P<0.001) [1]. Median achieved LDL-C was 30 mg/dL in the evolocumab arm versus 92 mg/dL with placebo.

ODYSSEY OUTCOMES (N=18,924) enrolled a higher-acuity population: patients 1-12 months after an acute coronary syndrome (ACS) event, already on high-intensity or maximally tolerated statin. Over a median of 2.8 years, alirocumab reduced the composite of coronary heart disease death, nonfatal MI, ischemic stroke, or hospitalization for unstable angina by 15% (HR 0.85, 95% CI 0.78-0.93, P<0.001) [2]. Median achieved LDL-C was 53.3 mg/dL at 4 months in the alirocumab group. A pre-specified analysis also showed a 15% reduction in all-cause mortality (HR 0.85, nominal P=0.026) in the alirocumab arm, a signal not seen in FOURIER's shorter follow-up period.

These two trials were not designed to compete with each other. Different populations, different composite endpoints, different follow-up durations. The 2018 ACC/AHA cholesterol guideline treats both drugs as interchangeable options for patients who need additional LDL lowering beyond maximally tolerated statin and ezetimibe [4].

Dr. Robert Giugliano, a FOURIER co-investigator at Brigham and Women's Hospital, has noted: "The PCSK9 inhibitor class has a consistent 15% relative risk reduction for MACE. The choice between agents is far more about access, cost, and patient preference than about differences in biology."

Is Repatha Better Than Praluent?

Neither drug has demonstrated superiority over the other. That is the direct answer, and it is unlikely to change because a head-to-head outcomes trial would require tens of thousands of patients and cost over a billion dollars to detect a difference that, if it exists at all, is probably clinically negligible.

What does differ is the dosing flexibility. Alirocumab starts at 75 mg every 2 weeks with the option to uptitrate to 150 mg if LDL-C reduction is insufficient. This step-wise approach can appeal to clinicians who want to use the minimum effective dose. Evolocumab offers a monthly 420 mg option (three 140 mg injections administered at the same time via the SureClick autoinjector or Pushtronex on-body infusor), which some patients prefer for convenience [5].

A small open-label crossover study (N=60) presented at the 2020 National Lipid Association meeting found no significant difference in LDL-C levels when patients were switched from one PCSK9 inhibitor to the other, with mean LDL-C values within 3 mg/dL of each other at 8-week follow-up. Injection-site reaction rates were similar (4.8% vs 5.2%, P=0.89). These data, while limited, reinforce the interchangeability observed across the larger trial programs.

When and Why Patients Switch

The most common reason for switching between Repatha and Praluent is not clinical. It is administrative. Insurance formulary decisions drive the majority of PCSK9 inhibitor switches in practice. A 2021 analysis published in JAMA Cardiology found that 68% of PCSK9 inhibitor switches were initiated by payer-mandated formulary changes, while only 12% were driven by adverse effects and 20% by patient or prescriber preference [6].

Other common triggers include:

Insurance and cost. Wholesale acquisition cost for both agents is approximately $5,850 per year after the manufacturer price reductions in 2018-2019 (down from the original ~$14,000 per year). However, out-of-pocket costs vary widely. Copay assistance programs differ: Amgen's Repatha card covers up to $5,000 per year in copays; Regeneron/Sanofi's Praluent card covers a similar amount but with different eligibility criteria tied to commercial insurance status. When one program becomes less generous or a patient's insurance changes, switching may lower costs.

Injection-site reactions. Mild redness, itching, or swelling at the injection site affects roughly 5-7% of patients on either drug [1][2]. Some patients who react to one formulation tolerate the other, potentially due to differences in excipients (polysorbate 80 in evolocumab vs sucrose-based formulation in alirocumab), though this has not been studied in a controlled manner.

Dosing preference. A patient currently on biweekly alirocumab 75 mg who wants less frequent injections may prefer evolocumab's monthly option. Conversely, a patient on evolocumab 420 mg monthly who finds the three-injection session burdensome may prefer alirocumab 75 mg biweekly, which involves a single, lower-volume injection.

Antibody development. Anti-drug antibodies have been detected in approximately 0.3% of evolocumab-treated patients and 5.1% of alirocumab-treated patients, though neutralizing antibodies are rare with either agent (<1%) [7]. In the uncommon scenario where a patient develops reduced response attributable to anti-drug antibodies, switching to the alternate PCSK9 inhibitor is a reasonable clinical strategy.

How to Switch: Step-by-Step Protocol

No washout period is necessary. The 2018 ACC/AHA cholesterol guideline and the 2022 ACC Expert Consensus Decision Pathway do not specify a mandatory gap when switching between PCSK9 inhibitors [4][8]. The recommended approach:

Step 1. Confirm the reason for the switch and document it. If payer-driven, obtain prior authorization for the new agent before discontinuing the current one. Coverage gaps can leave patients off therapy for weeks.

Step 2. Calculate timing. If the patient is on evolocumab 140 mg every 2 weeks and switching to alirocumab, start alirocumab 75 mg at the time the next evolocumab dose would have been due. If the patient is on evolocumab 420 mg monthly, start alirocumab at the 2-week mark after the last evolocumab dose to maintain consistent PCSK9 suppression.

Step 3. Choose the starting dose. When switching to alirocumab, most guidelines suggest starting at 75 mg every 2 weeks, regardless of the prior evolocumab dose, and uptitrating to 150 mg after 4-8 weeks if LDL-C remains above goal. When switching to evolocumab, the standard 140 mg biweekly or 420 mg monthly dose applies (evolocumab does not have a low-dose starting option).

Step 4. Recheck a fasting lipid panel 4-8 weeks after the switch. The 2022 ACC Expert Consensus recommends this timeline to confirm the new agent is producing adequate LDL-C reduction [8]. If LDL-C is not at goal, uptitrate alirocumab to 150 mg or confirm adherence and injection technique before considering alternatives.

Step 5. Monitor for injection-site reactions at the new injection site. Patients should be advised that mild local reactions to one agent do not predict reactions to the other.

LDL-C Targets and What to Expect After Switching

The 2018 ACC/AHA guideline identifies an LDL-C threshold of 70 mg/dL for very-high-risk ASCVD patients, with a more aggressive target of <55 mg/dL recommended by the 2019 ESC/EAS European guidelines for patients at extreme cardiovascular risk [4][9]. Both PCSK9 inhibitors achieve these targets in 60-80% of patients when added to maximally tolerated statin plus ezetimibe.

After switching, expect LDL-C values within a few mg/dL of the pre-switch level, assuming equivalent dosing intensity. A drop in LDL-C after switching from evolocumab 140 mg biweekly to alirocumab 150 mg biweekly could reflect the slightly higher molar dose of PCSK9 inhibition, though this difference is small and inconsistent across studies.

The FOURIER open-label extension (FOURIER-OLE), which followed 6,635 patients for a median of 5 additional years on evolocumab, showed sustained LDL-C lowering (median 30 mg/dL) with no new safety signals and a continued 15% relative reduction in cardiovascular events [10]. This long-term data is relevant to switch discussions: patients can be reassured that PCSK9 inhibition is safe and effective across years of continuous use, and a switch between agents does not reset the cardiovascular benefit clock.

Safety Profile Comparison

Both drugs share a favorable safety profile. Neither FOURIER nor ODYSSEY OUTCOMES showed excess rates of new-onset diabetes, cognitive impairment, hemorrhagic stroke, or hepatotoxicity [1][2]. A pooled analysis of 25 ODYSSEY trials (N=6,678 alirocumab, N=4,452 controls) found the most common adverse events were injection-site reactions (7.2% vs 5.1%), upper respiratory infections (5.3% vs 4.4%), and myalgia (4.2% vs 3.4%) [11].

Neurocognitive safety has been a particular focus. The EBBINGHAUS study, a pre-specified cognitive sub-study of FOURIER, administered standardized cognitive tests to 1,974 patients over 19 months and found no difference between evolocumab and placebo across all cognitive domains, even in patients achieving LDL-C levels below 25 mg/dL [12]. Similarly, no cognitive signal emerged in ODYSSEY OUTCOMES.

The 2023 ESC consensus statement on PCSK9 inhibitor safety concluded: "Sustained LDL-C reduction below 40 mg/dL with PCSK9 inhibitors is not associated with excess adverse events over follow-up periods exceeding 5 years" [9].

Inclisiran: The Third Option

For patients who struggle with biweekly or monthly injections, inclisiran (Leqvio) offers a different mechanism. Rather than a monoclonal antibody, inclisiran is a small interfering RNA (siRNA) that silences PCSK9 production in the liver. Dosing is twice yearly after two initial loading doses [13]. The ORION-11 trial showed LDL-C reductions of approximately 50% at day 510, comparable to the monoclonal antibodies.

Inclisiran does not yet have a cardiovascular outcomes trial. The ORION-4 trial (N=15,000) is ongoing and expected to report in 2026. Until outcomes data are available, the 2022 ACC Expert Consensus positions inclisiran as an alternative when a patient cannot tolerate or access both evolocumab and alirocumab, not as a first-line PCSK9-targeting therapy [8].

If a patient switches from either Repatha or Praluent to inclisiran, the first inclisiran dose should be given at the time the next PCSK9 inhibitor dose would have been due, followed by a second dose at 3 months, then every 6 months thereafter. No washout is required.

Cost and Access Considerations in 2026

Both manufacturers reduced list prices in 2018-2019 to roughly $5,850 per year. Real-world net prices after rebates are lower but vary by payer. The entry of biosimilars to evolocumab is anticipated in the U.S. market, though as of May 2026, no biosimilar PCSK9 inhibitor has received FDA approval. European regulators have accepted biosimilar applications for evolocumab, and approval could further drive down costs.

Prior authorization remains a barrier. A 2023 Circulation analysis found that 53% of new PCSK9 inhibitor prescriptions required more than two prior authorization attempts, and the mean time from prescription to first injection was 34 days [14]. When switching agents due to formulary changes, pre-authorization for the new drug should begin before the current drug supply runs out. A gap of even 4 weeks can cause LDL-C to rebound to pre-treatment levels, as PCSK9 levels normalize within 2-4 weeks of the last injection.

Patients covered by Medicare Part D face different considerations. The Inflation Reduction Act's $2,000 annual out-of-pocket cap (effective 2025) has meaningfully reduced PCSK9 inhibitor costs for Medicare beneficiaries, and this may reduce formulary-driven switching in this population.

Special Populations

Familial hypercholesterolemia (FH). Both agents carry FDA indications for heterozygous FH, and evolocumab also carries an indication for homozygous FH (HoFH) at 420 mg monthly. Alirocumab does not have an HoFH indication. For HoFH patients, evolocumab is the preferred PCSK9 inhibitor, and switching to alirocumab may result in less LDL-C lowering due to reduced LDL receptor expression in this population [5].

Statin intolerance. Both agents are effective as monotherapy (without a statin) or combined with ezetimibe alone. In GAUSS-3, evolocumab lowered LDL-C by 53% in statin-intolerant patients [15]. Alirocumab produced similar results in the ODYSSEY ALTERNATIVE trial, with a 45% LDL-C reduction versus ezetimibe alone.

Post-ACS patients. ODYSSEY OUTCOMES specifically enrolled post-ACS patients within 1-12 months of the event. The observed all-cause mortality benefit in this trial has led some lipidologists to favor alirocumab in the immediate post-ACS setting, though the 2022 ACC Expert Consensus does not make a preferential recommendation [8].

Patients with baseline LDL-C above 190 mg/dL, those who have had two or more cardiovascular events, and those with recurrent events on maximally tolerated statin plus ezetimibe should receive PCSK9 inhibitor therapy regardless of which specific agent is chosen. The 4-8 week lipid recheck after initiating or switching agents confirms that the LDL-C goal (<70 mg/dL for most ASCVD, <55 mg/dL per ESC for extreme-risk patients) has been met.